Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;37(7):699-708.
doi: 10.14670/HH-18-456. Epub 2022 Apr 6.

Histological diversity of anti-PD1-induced colitis

Affiliations

Histological diversity of anti-PD1-induced colitis

Stratigoula Sakellariou et al. Histol Histopathol. 2022 Jul.

Abstract

Aim: Histological data on anti-PD1-associated colitis are limited, while the colitis subtypes are still not clearly defined and different terms are being used. The aim of the study was to explore the histopathology of anti-PD1-induced colitis.

Methods and results: Colonic biopsies from 9 patients under anti-PD1 agents presenting diarrhea were examined. Histological evaluation revealed colitis of mild to moderate severity in almost all cases. Four distinct dominant histological patterns were identified with nearly the same incidence: Ulcerative colitis (UC)-like (n=2), GVHD-like (n=2), collagenous-like (n=3) and a mixed colitis pattern combining features of microscopic and UC-like colitis (n=2). The latter was additionally characterized by high crypt epithelium apoptosis and cryptitis with mixed inflammatory infiltrate. Thickening of the subepithelial band of collagen, detachment of the surface epithelium and increased apoptosis of the crypt epithelium were commonly encountered features, irrespective of colitis subtype. CD4/CD8 ratio was lower in the "combined" and higher in the GVHD-like subtype.

Conclusions: Anti-PD1-induced colitis is expressed by different patterns of injury which share distinct histological hallmarks harboring diagnostic value, while a "combined" colitis subtype is being established. The histological alterations are indicative of mucosa barrier damage after antΙ-PD1 treatment and its participation in the pathogenetic process.

PubMed Disclaimer

References

    1. Assarzadegan N., Montgomery E. and Anders R.A. (2018). Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 472, 125-133. - PubMed
    1. Bamias G., Delladetsima I., Perdiki M., Siakavellas S.I., Goukos D., Papatheodoridis G.V., Daikos G.L. and Gogas H. (2017). Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy. Cancer Invest. 35, 443-455. - PubMed
    1. Baroudjian B., Lourenco N., Pagès C., Chami I., Maillet M., Bertheau P., Bagot M., Gornet JM., Lebbé C. and Allez M. (2016). Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 26, 308-311. - PubMed
    1. Cheng J.H.Pezhouh M.K., Lauwers G.Y. and Masia R. (2017). Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 4, 643-654. - PubMed
    1. Cheung, V.T.F., Gupta, T., Olsson-Brown A., Subramanian S., Sasson S.C., Heseltine J., Fryer E., Collantes E., Sacco J.J., Pirmohamed M., Simmons A., Klenerman P., Tuthill M., Protheroe A.S., Chitnis M., Fairfax B.P., Payne M.J., Middleton M.R. and Brain O. (2020). Immune checkpoint inhibitor-related colitisassessment and prognosis: can IBD scoring point the way? Br. J. Cancer. 123, 207-215. - PMC - PubMed